REOPRO
LOE ApproachingmAbabciximab
BLAINJECTIONINJECTABLEPriority Review
Approved
Dec 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
11
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 21h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ReoPro (abciximab) is a chimeric human-murine monoclonal antibody that inhibits platelet aggregation by blocking the glycoprotein IIb/IIIa receptor. It is indicated for prevention of ischemic cardiac events in patients undergoing percutaneous coronary intervention. The drug represents a landmark intervention in acute coronary syndrome management, particularly for high-risk angioplasty patients.
LOE Approaching
With LOE approaching and moderate competitive pressure (30%), the ReoPro team is likely in defensive/transition mode, prioritizing retention over expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (11)
Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis
Started Nov 2013
0Sickle Cell DiseaseHb-SS Disease With Vasoocclusive PainHemoglobin SS Disease With Vasoocclusive Crisis+2 more
Exploratory P2 Trial to Evaluate Efficacy and Safety of Clotinab® (Abciximab) in Acute MI Patients
Started May 2013
146 enrolled
Acute Myocardial Infarction
Efficacy Of Eptifibatide Compared To Abciximab In Primary Percutaneous Coronary Intervention (PCI) For Acute ST Elevation Myocardial Infarction (STEMI)
Started Oct 2006
429 enrolled
Infarction, Myocardial
Abciximab in Patients Undergoing Percutaneous Coronary Intervention for Cardiogenic Shock
Started Sep 2006
80 enrolled
Shock, Cardiogenic
Efficacy Study on Early Versus Late Abciximab Administration During Primary Coronary Angioplasty
Started Apr 2006
110 enrolled
Myocardial Infarction
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.